## **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## **FORM 10-O**

#### (Mark One)

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

#### For the quarterly period ended June 30, 2013

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-14273

## **CORE LABORATORIES N.V.**

(Exact name of registrant as specified in its charter)

## The Netherlands

(State of other jurisdiction of incorporation or organization)

**Herengracht 424** 1017 BZ Amsterdam The Netherlands (Address of principal executive offices)

Not Applicable

Not Applicable (I.R.S. Employer Identification No.)

(31-20) 420-3191

(Registrant's telephone number, including area code)

None

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  $\boxtimes$  No  $\square$ 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  $\boxtimes$  No  $\square$ 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer 🗵 Accelerated filer  $\square$ Non-accelerated filer  $\Box$ Smaller reporting company  $\Box$ (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes 🗆 No 🗵

The number of common shares of the registrant, par value EUR 0.02 per share, outstanding at July 18, 2013 was 45,639,251.

(Zip Code)

## CORE LABORATORIES N.V. FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2013

## INDEX

## **PART I - FINANCIAL INFORMATION**

		Page
Iten	1. Financial Statements	
	Consolidated Balance Sheets (Unaudited) at June 30, 2013 and December 31, 2012	<u>1</u>
	Consolidated Statements of Operations (Unaudited) for the Three Months Ended June 30, 2013 and 2012	<u>2</u>
	Consolidated Statements of Operations (Unaudited) for the Six Months Ended June 30, 2013 and 2012	<u>3</u>
	Consolidated Statements of Comprehensive Income (Unaudited) for the Three and Six Months Ended June 30, 2013 and 2012	<u>4</u>
	Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2013 and 2012	<u>5</u>
	Notes to the Unaudited Consolidated Interim Financial Statements	<u>6</u>
Iten	2. Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>14</u>
Iten	3. Quantitative and Qualitative Disclosures About Market Risk	<u>23</u>
Iten	4. <u>Controls and Procedures</u>	<u>23</u>

## **PART II - OTHER INFORMATION**

<u>Item 1.</u>	Legal Proceedings	<u>24</u>
<u>Item 2.</u>	Unregistered Sales of Equity Securities and Use of Proceeds	<u>24</u>
<u>Item 6.</u>	<u>Exhibits</u>	<u>25</u>
	Signature	<u>26</u>
		_

## **PART I - FINANCIAL INFORMATION**

## CORE LABORATORIES N.V. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data)

	June 30, 2013			cember 31, 2012
ASSETS	J)	Unaudited)		
CURRENT ASSETS:	<b>.</b>		<i>.</i>	
Cash and cash equivalents	\$	23,220	\$	19,226
Accounts receivable, net of allowance for doubtful accounts of \$3,028 and \$3,516 at 2013 and 2012, respectively		190,867		184,774
Inventories		54,831		49,265
Prepaid expenses		15,538		14,959
Income tax receivable		11,183		17,943
Other current assets		13,045		10,740
TOTAL CURRENT ASSETS		308,684		296,907
PROPERTY, PLANT AND EQUIPMENT, net		130,829		125,418
INTANGIBLES, net		10,340		8,721
GOODWILL		163,337		163,337
DEFERRED TAX ASSETS, net		9,980		13,224
OTHER ASSETS		31,946		28,909
TOTAL ASSETS	\$	655,116	\$	636,516
LIABILITIES AND EQUITY				
CURRENT LIABILITIES:				
Accounts payable	\$	55,928	\$	55,168
Accrued payroll and related costs		30,124		34,919
Taxes other than payroll and income		10,288		11,787
Unearned revenue		16,358		13,868
Income tax payable		12,157		9,542
Other accrued expenses		16,101		15,226
TOTAL CURRENT LIABILITIES		140,956		140,510
LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS		250,013		234,033
DEFERRED COMPENSATION		31,470		28,112
DEFERRED TAX LIABILITIES, net		5,241		6,777
OTHER LONG-TERM LIABILITIES		39,958		39,171
COMMITMENTS AND CONTINGENCIES (Note 6)				
EQUITY:				
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding		_		_
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 47,899,584 issued and 45,709,251 outstanding at 2013 and 47,899,584 issued and 46,349,411 outstanding at 2012		1,233		1,233
Additional paid-in capital		110		
Retained earnings		447,612		361,255
Accumulated other comprehensive income (loss)		(8,210)		(8,413)
Treasury shares (at cost), 2,190,333 at 2013 and 1,550,173 at 2012		(259,432)		(171,845)
Total Core Laboratories N.V. shareholders' equity		181,313		182,230
Non-controlling interests		6,165		5,683
TOTAL EQUITY		187,478		187,913
TOTAL LIABILITIES AND EQUITY	\$	655,116	\$	636,516
	φ	033,110	Φ	030,310

## CORE LABORATORIES N.V. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data)

	Three Months End June 30,			
		2013		2012
		(Unau	ıdite	ed)
REVENUE:				
Services	\$	187,676	\$	175,749
Product sales		75,463	_	71,257
Total revenue		263,139		247,006
OPERATING EXPENSES:				
Cost of services, exclusive of depreciation expense shown below		109,661		103,926
Cost of product sales, exclusive of depreciation expense shown below		53,842		52,454
General and administrative expenses, exclusive of depreciation expense shown below		11,173		10,205
Depreciation		5,656		4,788
Amortization		308		289
Other (income) expense, net		630		3,218
OPERATING INCOME		81,869		72,126
Interest expense		2,263		2,178
Income before income tax expense		79,606		69,948
Income tax expense		19,664		16,997
Net income		59,942		52,951
Net income (loss) attributable to non-controlling interests		266		35
Net income attributable to Core Laboratories N.V.	\$	59,676	\$	52,916
EARNINGS PER SHARE INFORMATION:				
Basic earnings per share attributable to Core Laboratories N.V.	\$	1.30	\$	1.11
Diluted earnings per share attributable to Core Laboratories N.V.	\$	1.29	\$	1.11
Cash dividends per share	\$	0.32	\$	0.28
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:				
Basic		45,841	_	47,473
Diluted		46,128		47,791
	_			

## CORE LABORATORIES N.V. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data)

2013     2012 (Unaudited)       REVENUE:     S       Services     \$ 370,157     \$ 338,418       Product sales     153,909     142,779       Total revenue     524,066     481,197       OPERATING EXPENSES:     219,814     201,936       Cost of services, exclusive of depreciation expense shown below     219,814     201,936       Cost of product sales, exclusive of depreciation expense shown below     23,982     20,379       Depreciation     11,379     10,384       Amortization     610     576       Other (income) expense, net     41     (1,694)       OPERATING INCOME     160,906     146,032       Interest expense     4,532     4,368       Income before income tax expense     39,700     34,783       Net income (loss) attributable to non-controlling interests     482     14       Net income (loss) attributable to Core Laboratories N.V.     \$ 116,674     106,881       Ark income attributable to Core Laboratories N.V.     \$ 2.52     \$ 2.25       Diluted earnings per share attributable to Core Laboratories N.V.     \$ 2.51     \$ 2.237		Six Months Ende June 30,			
REVENUE:     S     370,157     \$     338,418       Product sales     153,909     142,779       Total revenue     524,066     481,197       OPERATING EXPENSES:     7000000000000000000000000000000000000			2013		2012
Services   \$ 370,157   \$ 338,418     Product sales   153,909   142,779     Total revenue   524,066   481,197     OPERATING EXPENSES:   219,814   201,936     Cost of services, exclusive of depreciation expense shown below   107,334   103,584     General and administrative expenses, exclusive of depreciation expense shown below   23,982   20,379     Depreciation   11,379   10,384     Amortization   610   576     Other (income) expense, net   41   (1,694)     OPERATING INCOME   160,906   146,032     Interest expense   4,532   4,368     Income before income tax expense   156,374   141,664     Income (loss) attributable to non-controlling interests   482   144     Net income (loss) attributable to non-controlling interests   482   144     Net income attributable to Core Laboratories N.V.   \$ 116,674   106,867     EARNINGS PER SHARE INFORMATION:   \$ 2.52   \$ 2.52   \$ 2.22     Basic earnings per share attributable to Core Laboratories N.V.   \$ 2.51   \$ 2.23     Cash dividends per share   \$ 0.64   \$ 0.56 <th></th> <th></th> <th>(Unau</th> <th>ıdit</th> <th>ed)</th>			(Unau	ıdit	ed)
Product sales     153,909     142,779       Total revenue     524,066     481,197       OPERATING EXPENSES:     219,814     201,936       Cost of services, exclusive of depreciation expense shown below     107,334     103,584       General and administrative expenses, exclusive of depreciation expense shown below     23,982     20,379       Depreciation     11,379     10,384       Amortization     610     576       Other (income) expense, net     41     (1,694)       OPERATING INCOME     160,906     146,032       Interest expense     4,532     4,368       Income before income tax expense     116,674     106,881       Net income (loss) attributable to non-controlling interests     482     144       Net income attributable to Core Laboratories N.V.     \$ 116,192     \$ 106,887       Basic earnings per share attributable to Core Laboratories N.V.     \$ 2.52     \$ 2.52     \$ 2.52       Diluted earnings per share attributable to Core Laboratories N.V.     \$ 2.51     \$ 2.52     \$ 2.23       Cash dividends per share     \$ 0.64     \$ 0.56     \$ 0.56       WEIGHTED AVERAGE COMMON S	REVENUE:				
Total revenue $524,066$ $481,197$ OPERATING EXPENSES:219,814201,936Cost of services, exclusive of depreciation expense shown below107,334103,584General and administrative expenses, exclusive of depreciation expense shown below23,98220,379Depreciation11,37910,384Amortization610576Other (income) expense, net41(1,694)OPERATING INCOME160,906146,032Interest expense4,5324,368Income before income tax expense156,374141,664Income tax expense39,70034,783Net income (loss) attributable to non-controlling interests48214Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867EARNINGS PER SHARE INFORMATION:\$ 2.52\$ 2.23Basic earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.52South expense\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:\$ 46,02047,539	Services	\$	370,157	\$	338,418
OPERATING EXPENSES:Cost of services, exclusive of depreciation expense shown below219,814201,936Cost of product sales, exclusive of depreciation expense shown below107,334103,584General and administrative expenses, exclusive of depreciation expense shown below23,98220,379Depreciation11,37910,384Amortization610576Other (income) expense, net41(1,694)OPERATING INCOME160,906146,032Interest expense4,5324,368Income before income tax expense156,374141,664Income tax expense39,70034,783Net income (loss) attributable to non-controlling interests48214Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867EARNINGS PER SHARE INFORMATION:\$ 2.52\$ 2.25Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.52Basic earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.23Gash dividends per share\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:\$ 46,02047,539	Product sales		153,909		142,779
Cost of services, exclusive of depreciation expense shown below219,814201,936Cost of product sales, exclusive of depreciation expense shown below107,334103,584General and administrative expenses, exclusive of depreciation expense shown below23,98220,379Depreciation11,37910,384Amortization610576Other (income) expense, net41(1,694)OPERATING INCOME160,906146,032Interest expense4,5324,368Income before income tax expense156,374141,664Income tax expense39,70034,783Net income (loss) attributable to non-controlling interests48214Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867EARNINGS PER SHARE INFORMATION:\$ 2.51\$ 2.23\$ 2.25Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.23Cash dividends per share\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:\$ 0.64\$ 0.56Basic46,02047,539	Total revenue		524,066		481,197
Cost of product sales, exclusive of depreciation expense shown below $107,334$ $103,584$ General and administrative expenses, exclusive of depreciation expense shown below $23,982$ $20,379$ Depreciation $11,379$ $10,384$ Amortization $610$ $576$ Other (income) expense, net $41$ $(1,694)$ OPERATING INCOME $160,906$ $146,032$ Interest expense $4,532$ $4,368$ Income before income tax expense $156,374$ $141,664$ Income tax expense $39,700$ $34,783$ Net income (loss) attributable to non-controlling interests $482$ $14$ Net income attributable to Core Laboratories N.V.§ $116,192$ § $106,867$ EARNINGS PER SHARE INFORMATION: $8$ $2.51$ § $2.52$ Diluted earnings per share attributable to Core Laboratories N.V.§ $2.51$ § $2.231$ Cash dividends per share§ $0.64$ § $0.56$ WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: $8$ $0.56$ Basic $46,020$ $47,539$	OPERATING EXPENSES:				
General and administrative expenses, exclusive of depreciation expense shown below23,98220,379Depreciation11,37910,384Amortization610576Other (income) expense, net41(1,694)OPERATING INCOME160,906146,032Interest expense4,5324,368Income before income tax expense156,374141,664Income tax expense39,70034,783Net income116,674106,881Net income (loss) attributable to non-controlling interests48214Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867Basic earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.25Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.23Cash dividends per share\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:8 0.64\$ 0.56Basic46,02047,539	Cost of services, exclusive of depreciation expense shown below		219,814		201,936
Depreciation11,37910,384Amortization610576Other (income) expense, net41(1,694)OPERATING INCOME160,906146,032Interest expense4,5324,368Income before income tax expense156,374141,664Income tax expense39,70034,783Net income116,674106,881Net income (loss) attributable to non-controlling interests48214Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867Basic earnings per share attributable to Core Laboratories N.V.\$ 2.52\$ 2.25Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.52Basic earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.23Cash dividends per share\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:#46,02047,539	Cost of product sales, exclusive of depreciation expense shown below		107,334		103,584
Amortization $610$ $576$ Other (income) expense, net $41$ $(1,694)$ OPERATING INCOME $160,906$ $146,032$ Interest expense $4,532$ $4,368$ Income before income tax expense $156,374$ $141,664$ Income tax expense $39,700$ $34,783$ Net income $116,674$ $106,881$ Net income (loss) attributable to non-controlling interests $482$ $14$ Net income attributable to Core Laboratories N.V. $\$$ $116,192$ $\$$ Basic earnings per share attributable to Core Laboratories N.V. $\$$ $2.52$ $\$$ $2.23$ Diluted earnings per share attributable to Core Laboratories N.V. $\$$ $2.51$ $\$$ $2.23$ Basic earnings per share attributable to Core Laboratories N.V. $\$$ $2.51$ $\$$ $2.23$ Diluted earnings per share attributable to Core Laboratories N.V. $\$$ $2.51$ $\$$ $2.23$ Basic $6.64$ $0.56$ $$0.64$ $$0.56$ WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: $$46,020$ $47,539$	General and administrative expenses, exclusive of depreciation expense shown below		23,982		20,379
Other (income) expense, net $41$ (1,694)OPERATING INCOME160,906146,032Interest expense $4,532$ $4,368$ Income before income tax expense156,374141,664Income tax expense39,70034,783Net income116,674106,881Net income (loss) attributable to non-controlling interests $482$ 14Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867EARNINGS PER SHARE INFORMATION: $$ 2.52$ \$ 2.25Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.23Cash dividends per share\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: $$ 46,020$ $47,539$	Depreciation		11,379		10,384
OPERATING INCOME160,906146,032Interest expense4,5324,368Income before income tax expense156,374141,664Income tax expense39,70034,783Net income116,674106,881Net income (loss) attributable to non-controlling interests48214Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867EARNINGS PER SHARE INFORMATION:\$ 2.52\$ 2.25Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.52Cash dividends per share\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:\$ 46,02047,539	Amortization		610		576
Interest expense $4,532$ $4,368$ Income before income tax expense $156,374$ $141,664$ Income tax expense $39,700$ $34,783$ Net income $116,674$ $106,881$ Net income (loss) attributable to non-controlling interests $482$ $14$ Net income attributable to Core Laboratories N.V. $$116,192$ $$106,867$ EARNINGS PER SHARE INFORMATION: $$2.52$ $$2.52$ $$2.25$ Diluted earnings per share attributable to Core Laboratories N.V. $$2.51$ $$2.51$ $$2.23$ Cash dividends per share $$0.64$ $$0.56$ $$0.56$ WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: $$46,020$ $47,539$	Other (income) expense, net		41		(1,694)
Income before income tax expense156,374141,664Income tax expense39,70034,783Net income116,674106,881Net income (loss) attributable to non-controlling interests48214Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867EARNINGS PER SHARE INFORMATION:\$ 2.52\$ 2.25Basic earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.52Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.23Cash dividends per share\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:#46,02047,539	OPERATING INCOME		160,906		146,032
Income tax expense $39,700$ $34,783$ Net income116,674106,881Net income (loss) attributable to non-controlling interests $482$ 14Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867EARNINGS PER SHARE INFORMATION: $32,52$ \$ 2.52\$ 2.25Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.51\$ 2.23Cash dividends per share\$ 0.64\$ 0.56 $34,783$ WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: $46,020$ $47,539$	Interest expense		4,532		4,368
Net income116,674106,881Net income (loss) attributable to non-controlling interests48214Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867EARNINGS PER SHARE INFORMATION:52.52\$ 2.25Basic earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.52Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.23Cash dividends per share\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:46,02047,539	Income before income tax expense		156,374		141,664
Net income (loss) attributable to non-controlling interests48214Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867EARNINGS PER SHARE INFORMATION:Basic earnings per share attributable to Core Laboratories N.V.\$ 2.52\$ 2.25Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.51Cash dividends per share\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:46,02047,539	Income tax expense		39,700		34,783
Net income attributable to Core Laboratories N.V.\$ 116,192\$ 106,867EARNINGS PER SHARE INFORMATION:Basic earnings per share attributable to Core Laboratories N.V.\$ 2.52\$ 2.25Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51\$ 2.51Cash dividends per share\$ 0.64\$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:46,02047,539	Net income		116,674		106,881
EARNINGS PER SHARE INFORMATION:Basic earnings per share attributable to Core Laboratories N.V.\$ 2.52 \$ 2.25Diluted earnings per share attributable to Core Laboratories N.V.\$ 2.51 \$ 2.23Cash dividends per share\$ 0.64 \$ 0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:46,020 47,539	Net income (loss) attributable to non-controlling interests		482		14
Basic earnings per share attributable to Core Laboratories N.V.\$2.52\$2.25Diluted earnings per share attributable to Core Laboratories N.V.\$2.51\$2.23Cash dividends per share\$0.64\$0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:46,02047,539	Net income attributable to Core Laboratories N.V.	\$	116,192	\$	106,867
Diluted earnings per share attributable to Core Laboratories N.V.\$2.51\$2.23Cash dividends per share\$0.64\$0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:46,02047,539	EARNINGS PER SHARE INFORMATION:				
Cash dividends per share\$0.64\$0.56WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: </td <td>Basic earnings per share attributable to Core Laboratories N.V.</td> <td></td> <td>2.52</td> <td>\$</td> <td>2.25</td>	Basic earnings per share attributable to Core Laboratories N.V.		2.52	\$	2.25
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic 46,020 47,539	Diluted earnings per share attributable to Core Laboratories N.V.		2.51	\$	2.23
Basic 46,020 47,539	Cash dividends per share	\$	0.64	\$	0.56
	WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:				
Diluted 46,313 47,868	Basic		46,020		47,539
	Diluted		46,313	_	47,868

## CORE LABORATORIES N.V. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (In thousands)

	Three Months Ended June 30,					Ended ),				
		2013	2012		2012		2013			2012
		(Unau	(Unaudited) (Una		lited) (U		ıdit	ed)		
Net income	\$	59,942	\$	52,951	\$	116,674	\$	106,881		
Pension and other postretirement benefit plans										
Prior service cost										
Amortization to net income of transition asset		(22)		(22)		(44)		(44)		
Amortization to net income of prior service cost		40		40		80		80		
Amortization to net income of actuarial loss		117				234		_		
Income taxes on pension and other postretirement benefit plans		(34)		(5)		(68)		(9)		
Comprehensive income		60,043		52,964		116,876		106,908		
Comprehensive income (loss) attributable to non-controlling interests		266		35		482		14		
Comprehensive income attributable to Core Laboratories N.V.	\$	59,777	\$	52,929	\$	116,394	\$	106,894		

## CORE LABORATORIES N.V. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)

	Six Months Ender June 30,		
	2013	2012	
	(Una	udited)	
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net income	\$ 116,674	\$ 106,881	
Adjustments to reconcile net income to net cash provided by operating activities:			
Stock-based compensation	10,176		
Depreciation and amortization	11,989	,	
(Gain) on insurance recovery	(546	/ /	
(Increase) decrease in value of life insurance policies	(1,456		
Deferred income taxes	(709		
Other non-cash items	126	597	
Changes in assets and liabilities:			
Accounts receivable	(5,345		
Inventories	(6,168		
Prepaid expenses and other current assets	5,433		
Other assets	(450	· · · ·	
Accounts payable	2,081		
Accrued expenses	(1,939		
Unearned revenue	2,490		
Other long-term liabilities	4,145		
Net cash provided by operating activities	136,501	100,894	
CASH FLOWS FROM INVESTING ACTIVITIES:			
Capital expenditures	(17,935	(14,894)	
Patents and other intangibles	(2,229		
Cash (advanced)/settled for acquisition		- 1,632	
Proceeds from sale of assets	697		
Proceeds from insurance recovery		· 101	
Premiums on life insurance	(1,527		
Net cash used in investing activities	(20,994	(14,754)	
CASH FLOWS FROM FINANCING ACTIVITIES:			
Repayment of debt	(35,025	(48,744)	
Proceeds from debt	51,000	30,000	
Stock options exercised	83	5	
Excess tax benefits from stock-based compensation	2,353	3,466	
Debt financing costs		. (7)	
Dividends paid	(29,508	) (26,624)	
Repurchase of common shares	(100,416	(50,160)	
Net cash used in financing activities	(111,513		
NET CHANGE IN CASH AND CASH EQUIVALENTS	3,994	(5,924)	
CASH AND CASH EQUIVALENTS, beginning of period	19,226		
CASH AND CASH EQUIVALENTS, end of period	\$ 23,220	\$ 23,408	

## CORE LABORATORIES N.V. NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

## 1. BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements include the accounts of Core Laboratories N.V. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP and should be read in conjunction with the financial statements and the summary of significant accounting policies and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2012 (the "2012 Annual Report").

Core Laboratories N.V. uses the equity method of accounting for investments in which it has less than a majority interest and over which it does not exercise control. Non-controlling interests have been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned. In the opinion of management, all adjustments considered necessary for a fair statement of the results for the interim periods presented have been included in these financial statements. Furthermore, the operating results presented for the three and six months ended June 30, 2013 may not necessarily be indicative of the results that may be expected for the year ended December 31, 2013.

Core Laboratories N.V.'s balance sheet information for the year ended December 31, 2012 was derived from the 2012 audited consolidated financial statements but does not include all disclosures in accordance with U.S. GAAP.

Certain reclassifications were made to prior period amounts in order to conform to the current period presentation. These reclassifications had no impact on the reported net income or cash flows for the three and six month periods ended June 30, 2012.

References to "Core Lab", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated subsidiaries.

## 2. INVENTORIES

Inventories consist of the following (in thousands):

		ıne 30, 2013	Dec	ember 31, 2012
	(Un	audited)		
Finished goods	\$	43,598	\$	38,572
Parts and materials		9,086		8,818
Work in progress		2,147		1,875
Total inventories	\$	54,831	\$	49,265

We include freight costs incurred for shipping inventory to customers in the Cost of product sales line of the Consolidated Statements of Operations.

#### **3. GOODWILL AND INTANGIBLES**

We account for intangible assets with indefinite lives, including goodwill, in accordance with the applicable accounting guidance, which requires us to evaluate these assets for impairment annually or more frequently if an indication of impairment is possible. Based upon our most recent evaluation, we determined that goodwill is not impaired. We amortize intangible assets with a finite life on a straight-line basis over their respective useful lives.

## 4. DEBT AND CAPITAL LEASE OBLIGATIONS

Debt is summarized in the following table (in thousands):

	J	une 30, 2013	Dec	cember 31, 2012
	(Ui	naudited)		
Senior notes	\$	150,000	\$	150,000
Credit facility		100,000		84,000
Capital lease obligations		48		73
Total debt	_	250,048		234,073
Less - current maturities of long-term debt and capital lease obligations		35		40
Long-term debt and capital lease obligations, net	\$	250,013	\$	234,033

In 2011, we issued two series of senior notes with an aggregate principal amount of \$150 million ("Senior Notes") in a private placement transaction. Series A consists of \$75 million in aggregate principal amount of notes that bear interest at a fixed rate of 4.01% and are due in full on September 30, 2021. Series B consists of \$75 million in aggregate principal amount of notes that bear interest at a fixed rate of 4.11% and are due in full on September 30, 2021. Series B consists of \$75 million in aggregate principal amount of notes that bear interest at a fixed rate of 4.11% and are due in full on September 30, 2023. Interest on each series of the Senior Notes is payable semi-annually on March 30 and September 30.

We maintain a credit facility (the "Credit Facility") with an aggregate borrowing capacity of \$300 million at June 30, 2013. The Credit Facility provides an option to increase the commitment under the Credit Facility to \$350 million, if certain conditions are met. The Credit Facility bears interest at variable rates from LIBOR plus 1.50% to a maximum of LIBOR plus 2.25%. Any outstanding balance under the Credit Facility is due September 28, 2016 when the Credit Facility matures. Interest payment terms are variable depending upon the specific type of borrowing under this facility. Our available capacity at any point in time is reduced by borrowings outstanding at the time and outstanding letters of credit which totaled \$18.7 million at June 30, 2013, resulting in an available borrowing capacity under the Credit Facility of \$181.3 million. In addition to those items under the Credit Facility, we had \$21.9 million of outstanding letters of credit and performance guarantees and bonds from other sources as of June 30, 2013.

The terms of the Credit Facility and the Senior Notes require us to meet certain financial and operational covenants, including, but not limited to, certain operational and minimum equity and cash flow ratios. We believe that we are in compliance with all such covenants contained in our credit agreements. Certain of our material, wholly-owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes.

The estimated fair value of total debt at June 30, 2013 and December 31, 2012 approximated the book value of total debt. The fair value was estimated using Level 2 inputs by calculating the sum of the discounted future interest and principal payments through the date of maturity.

## 5. PENSIONS AND OTHER POSTRETIREMENT BENEFITS

#### **Defined Benefit Plan**

We provide a noncontributory defined benefit pension plan covering substantially all of our Dutch employees (the "Dutch Plan") who were hired prior to 2007 based on years of service and final pay or career average pay, depending on when the employee began participating. The benefits earned by the employees are immediately vested. We fund the future obligations of the Dutch Plan by purchasing insurance contracts from a large multi-national insurance company. The insurance contracts are purchased annually and renew after five years at which time they are replaced with new contracts that are adjusted to include changes in the benefit obligation for the current year and redemption of the expired contracts. We make annual premium payments to the insurance company based on each employee's age and current salary, and the contractual growth rate. We determine the fair value of these plan assets with the assistance of an actuary using observable inputs (Level 2), which approximates the contract value of the investments.

The following table summarizes the components of net periodic pension cost under the Dutch Plan for the three and six months ended June 30, 2013 and 2012 (in thousands):

	Three Months Ended June 30,					Six Months Ended June 30,			
	2	.013	2	2012	2013		2	2012	
		(Unau	dited	)	(Unaudited)			i)	
Service cost	\$	388	\$	285	\$	784	\$	572	
Interest cost		411		425		831		853	
Expected return on plan assets		(317)		(304)		(640)		(610)	
Amortization of transition asset		(22)		(22)		(44)		(44)	
Amortization of prior service cost		40		40		80		80	
Amortization of actuarial loss		117				234		_	
Net periodic pension cost	\$	617	\$	424	\$	1,245	\$	851	

During the six months ended June 30, 2013, we contributed approximately \$2.0 million to fund the estimated 2013 premiums on investment contracts held by the Dutch Plan.

#### **Defined Contribution Plans**

We maintain five defined contribution plans (the "Defined Contribution Plans") for the benefit of eligible employees in Canada, The Netherlands, Puerto Rico, the United Kingdom and the United States. In accordance with the terms of each plan, we and our participating employees contribute up to specified limits, and under certain plans, we may make discretionary contributions consistent with the terms of each plan.

#### **Deferred Compensation Arrangements**

We have entered into deferred compensation contracts for certain key employees. The benefits under these contracts are fully vested and benefits are paid when the participants attain 65 years of age. Life insurance policies with cash surrender values have been purchased for the purpose of assisting in the funding of the deferred compensation contracts.

We have also adopted a non-qualified deferred compensation plan that allows certain highly compensated employees to defer a portion of their salary, commission and bonus, as well as the amount of any reductions in their deferrals under the deferred compensation plan for employees in the United States (the "Deferred Compensation Plan"), due to certain limitations imposed by the U.S. Internal Revenue Code of 1986, as amended (the "Internal Revenue Code"). The Deferred Compensation Plan also provides for employer contributions to be made on behalf of participants equal in amount to certain forfeitures of, and/or reductions in, employer contributions that participants could have received under the 401(k) Plan in the absence of certain limitations imposed by the Internal Revenue Code. Employer contributions to the Deferred Compensation Plan vest ratably over a period of five years. Contributions to the plan are invested in equity and other investment fund assets within life insurance policies and carried on the balance sheet at fair value. A participant's plan benefits include the participant's deferrals, the vested portion of the employer's contributions, and deemed investment gains and losses on such amounts.

On a recurring basis, we use the market approach to value certain assets and liabilities at fair value at quoted prices in an active market (Level 1) and certain assets and liabilities using significant other observable inputs (Level 2) with the assistance of a third party specialist. We do not have any assets or liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3). Gains and losses related to the fair value changes in the deferred compensation assets and liabilities are recorded in General and Administrative Expenses in the Consolidated Statements of Operations. The following table summarizes the fair value balances (in thousands):

(Unaudited)		Fair Value Measurement at June 30, 2013									
	Total	tal Level 1			Level 2	Le	evel 3				
Assets:											
Deferred compensation trust assets <sup>(1)</sup>	\$ 13,981	\$	—	\$	13,981	\$	—				
Liabilities:											
Deferred compensation plan	\$ 21,046	\$	2,438	\$	18,608	\$					

			Fair Value Measurement at December 31, 2012							
	Total			Level 1	Ι	Level 2	L	evel 3		
Assets:										
Deferred compensation trust assets <sup>(1)</sup>	\$	12,654	\$		\$	12,654	\$	—		
Liabilities:							-			
Deferred compensation plan	\$	18,579	\$	2,667	\$	15,912	\$	_		
	_		-		-		-			

(1) Trust assets consist of the cash surrender value of life insurance policies and are intended to assist in the funding of the deferred compensation plan.

## 6. COMMITMENTS AND CONTINGENCIES

We have been and may from time to time be named as a defendant in legal actions that arise in the ordinary course of business. These include, but are not limited to, employment-related claims and contractual disputes or claims for personal injury or property damage which occur in connection with the provision of our services and products. Management does not currently believe that any of our pending contractual, employment-related, personal injury or property damage claims and disputes will have a material effect on our future results of operations, financial position or cash flow.

In connection with an audit of the 2008 and 2009 U.S. federal income tax returns of our U.S. consolidated group, the U.S. Internal Revenue Service has proposed that certain transfer pricing positions taken by the Company be adjusted, which could result in additional federal income tax of approximately \$11 million plus interest for this two year audit period. We believe that these transactions are valid as originally recorded, and we are appealing this proposed adjustment. It is our belief that we will prevail on this issue; consequently, we have made no additional income tax accrual for this proposed adjustment.

#### 7. EQUITY

During the three months ended June 30, 2013, we repurchased 377,969 of our common shares for \$52.7 million. Included in this total were rights to 20,469 shares valued at \$2.9 million that were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participants' tax burdens that may result from the issuance of common shares under that plan. During the six months ended June 30, 2013, we repurchased 742,510 of our common shares for \$100.4 million. Included in this total were rights to 26,333 shares valued at \$3.7 million that were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participants' tax burdens that may result from the issuance of common shares of a stock-based compensation plan in consideration of the participants' tax burdens that may result from the issuance of common shares under that plan. Such common shares, unless canceled, may be reissued for a variety of purposes such as future acquisitions, non-employee director stock awards or employee stock awards.

In February and May 2013, we paid a quarterly dividend of \$0.32 per share of common stock. In addition, on July 9, 2013, we declared a quarterly dividend of \$0.32 per share of common stock for shareholders of record on July 19, 2013 and payable on August 19, 2013.

The following table summarizes our changes in equity for the six months ended June 30, 2013 (in thousands):

(Unaudited)	 mmon nares	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Non- Controlling Interests	Total Equity
December 31, 2012	\$ 1,233	\$ —	\$ 361,255	\$ (8,413)	\$ (171,845)	\$ 5,683	\$ 187,913
Stock options exercised	_	(1,411)	_	_	1,494	_	83
Stock based-awards	—	(832)	(327)		11,335		10,176
Tax benefit of stock- based awards issued		2,353	_	_	_	_	2,353
Repurchase of common shares		_	_	_	(100,416)		(100,416)
Dividends paid	—		(29,508)	—			(29,508)
Amortization of deferred pension costs, net of tax	_	_		203	_	_	203
Net income (loss)			116,192			482	116,674
June 30, 2013	\$ 1,233	\$ 110	\$ 447,612	\$ (8,210)	\$ (259,432)	\$ 6,165	\$ 187,478

Accumulated other comprehensive income (loss) consisted of the following (in thousands):

		ne 30, 013	December 31, 2012		
	(Una	udited)			
Prior service cost	\$	(556)	\$	(616)	
Transition asset		162		195	
Unrecognized net actuarial loss		(7,816)		(7,992)	
Total accumulated other comprehensive income (loss)	\$	(8,210)	\$	(8,413)	

## 8. EARNINGS PER SHARE

We compute basic earnings per common share by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common and potential common shares include additional shares in the weighted average share calculations associated with the incremental effect of dilutive employee stock options, restricted stock awards and contingently issuable shares, as determined using the treasury stock method. The following table summarizes the calculation of weighted average common shares outstanding used in the computation of diluted earnings per share (in thousands):

	Three Month	ns Ended	Six Months Ended June 30,		
	June 3	60,			
-	2013 2012		2013	2012	
•	(Unaudi	ted)	(Unaudited)		
Weighted average basic common shares outstanding	45,841	47,473	46,020	47,539	
Effect of dilutive securities:					
Stock options	—	11	2	12	
Performance shares	116	133	105	124	
Restricted stock	171	174	186	193	
Weighted average diluted common and potential common shares outstanding	46,128	47,791	46,313	47,868	

## 9. OTHER (INCOME) EXPENSE, NET

The components of other (income) expense, net, were as follows (in thousands):

	ŗ	Three Months E June 30,	nded	Six Months Ended June 30,			
	2013		2012	2013	2012		
		(Unaudited)	)	(Unaudit	ed)		
(Gain) loss on sale of assets	\$	(323) \$	(227) \$	(532) \$	(313)		
Results of non-consolidated subsidiaries		(89)	(181)	(185)	(247)		
Foreign exchange (gain) loss		1,631	1,355	2,522	330		
Interest income		(219)	(13)	(590)	(15)		
Rents and royalties		(213)	(255)	(443)	(595)		
(Gain) loss on insurance recovery		(7)	(101)	(546)	(3,467)		
Legal entity realignment			1,860		1,860		
NYSE Euronext Amsterdam listing			683		923		
Other, net		(150)	97	(185)	(170)		
Total other (income) expense, net	\$	630 \$	3,218 \$	41 \$	(1,694)		

We incurred property losses during Hurricane Isaac in 2012. During the first quarter of 2013, the insurer agreed to pay \$0.9 million of the claim which resulted in a net gain of \$0.5 million after related expenses and the disposal of the assets. We received this initial payment during the second quarter of 2013 and the insurer is continuing to review the remainder of the claim.

During the second quarter of 2012, we incurred legal, accounting and other fees in connection with the realignment of certain of our legal entities into a more cost effective structure and the listing of our shares on the NYSE Euronext Amsterdam Stock Exchange.

As a result of a supply disruption in 2011 from a key vendor that provided certain high performance specialty steel tubulars used with our perforating systems, we filed a claim under our business interruption insurance policy. We recorded a gain of \$3.4 million in the first quarter of 2012 when the initial payment was received from the insurance carrier.

Foreign exchange (gain) loss by currency is summarized in the following table (in thousands):

	r	Three Mor June			Six Months Ended June 30,				
		2013		2012		2013		2012	
		(Unaudited)				(Unaudited)			
Australian Dollar	\$	164	\$	(11)	\$	209	\$	(15)	
British Pound		79		48		541		59	
Canadian Dollar		665		519		968		(18)	
Euro		126		238		354		(7)	
Malaysian Ringgit		106		130		188		79	
Mexican Peso		191		191		64		39	
Russian Ruble		(60)		(16)		(54)		(56)	
Other currencies, net		360		256		252		249	
Total (gain) loss	\$	1,631	\$	1,355	\$	2,522	\$	330	

## **10. INCOME TAX EXPENSE**

The effective tax rates for the three months ended June 30, 2013 and 2012 were 24.7% and 24.3%, respectively. The effective tax rates for the year-to-date 2013 and 2012 were 25.4% and 24.6%, respectively. Included in the six months ended June 30, 2012 is the reversal of \$1.1 million in tax valuation allowance related to various jurisdictions.

#### **11. SEGMENT REPORTING**

We operate our business in three reportable segments: (1) Reservoir Description, (2) Production Enhancement and (3) Reservoir Management. These operating segments provide different services and utilize different technologies.

- *Reservoir Description:* Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.
- *Production Enhancement:* Includes services and products relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
- *Reservoir Management:* Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.

Results for these operating segments are presented below. We use the same accounting policies to prepare our business segment results as are used to prepare our Consolidated Financial Statements. All interest and other non-operating income (expense) is attributable to the Corporate & Other area and is not allocated to specific business segments. Summarized financial information concerning our segments is shown in the following table (in thousands):

(Unaudited)	Reservoir Description		Production Enhancement		Reservoir Management		Corporate & Other <sup>1</sup>		Consolidated	
Three Months Ended June 30, 2013										
Revenues from unaffiliated customers	\$	129,222	\$	110,199	\$	23,718	\$		\$	263,139
Inter-segment revenues		1,090		740		400		(2,230)		_
Segment operating income (loss)		36,918		37,239		7,475		237		81,869
Total assets (at end of period)		299,399		255,987		35,570		64,160		655,116
Capital expenditures		6,424		1,851		517		700		9,492
Depreciation and amortization		3,599		1,797		189		379		5,964
Three Months Ended June 30, 2012										
Revenues from unaffiliated customers	\$	126,462	\$	99,547	\$	20,997	\$		\$	247,006
Inter-segment revenues		760		615		785		(2,160)		_
Segment operating income (loss)		38,076		29,564		7,113		(2,627)		72,126
Total assets (at end of period)		279,823		246,837		24,756		71,257		622,673
Capital expenditures		3,667		2,426		29		1,475		7,597
Depreciation and amortization		3,445		902		175		555		5,077
Six Months Ended June 30, 2013										
Revenues from unaffiliated customers	\$	254,467	\$	217,630	\$	51,969	\$		\$	524,066
Inter-segment revenues		1,475		1,677		823		(3,975)		—
Segment operating income (loss)		71,769		71,477		17,321		339		160,906
Total assets		299,399		255,987		35,570		64,160		655,116
Capital expenditures		11,853		3,939		1,036		1,107		17,935
Depreciation and amortization		7,224		3,614		380		771		11,989
Six Months Ended June 30, 2012										
Revenues from unaffiliated customers	\$	242,568	\$	196,280	\$	42,349	\$		\$	481,197
Inter-segment revenues		1,296		1,083		804		(3,183)		_
Segment operating income (loss)		70,491		63,095		15,028		(2,582)		146,032
Total assets		279,823		246,837		24,756		71,257		622,673
Capital expenditures		6,146		4,268		440		4,040		14,894
Depreciation and amortization		6,992		2,500		342		1,126		10,960

(1) "Corporate & Other" represents those items that are not directly related to a particular segment and eliminations.

## **12. RECENT ACCOUNTING PRONOUNCEMENTS**

In February 2013, the FASB issued ASU 2013-02 relating to comprehensive income (FASB ASC Topic 220), which requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component (the respective line items of net income). This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. We adopted this pronouncement for our fiscal year beginning January 1, 2013. The adoption of this pronouncement did not have a material effect on our consolidated financial statements.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion summarizes the financial position of Core Laboratories N.V. and its subsidiaries as of June 30, 2013 and should be read in conjunction with (i) the unaudited consolidated interim financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q and (ii) the consolidated financial statements and accompanying notes to our Annual Report on Form 10-K for the fiscal year ended December 31, 2012 (the "2012 Annual Report").

## General

Core Laboratories N.V. is a Netherlands limited liability company. It was established in 1936 and is one of the world's leading providers of proprietary and patented reservoir description, production enhancement and reservoir management services and products to the oil and gas industry. These services and products can enable our clients to improve reservoir performance and increase oil and gas recovery from their producing fields. Core Laboratories N.V. has over 70 offices in more than 50 countries and employs approximately 5,000 people worldwide.

References to "Core Lab", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated affiliates.

Our business units have been aggregated into three complementary segments, which provide services and products for improving reservoir performance and increasing oil and gas recovery from new and existing fields.

- *Reservoir Description:* Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.
- *Production Enhancement:* Includes services and products relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
- *Reservoir Management:* Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs.

#### **Cautionary Statement Regarding Forward-Looking Statements**

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Certain statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations section, including those under the headings "Outlook" and "Liquidity and Capital Resources", and in other parts of this Form 10-Q, are forward-looking. In addition, from time to time, we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. Forward-looking statements can be identified by the use of forward-looking terminology such as "may", "will", "believe", "expect", "anticipate", "estimate", "continue", or other similar words, including statements as to the intent, belief, or current expectations of our directors, officers, and management with respect to our future operations, performance, or positions or which contain other forward-looking information. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. While management believes that these forward-looking statements are reasonable as and when made, no assurances can be given that the future results indicated, whether expressed or implied, will be achieved. While we believe that these statements are and will be accurate, our actual results and experience may differ materially from the anticipated results or other expectations expressed in our statements due to a variety of risks and uncertainties.

The oil and gas industry is highly cyclical and demand for the majority of our oilfield services and products is substantially dependent on the level of expenditures by the oil and gas industry for the exploration, development and production of crude oil and natural gas reserves, which are sensitive to oil and natural gas prices and generally dependent on the industry's view of future oil and gas prices. There are numerous factors affecting the supply of and demand for our services and products, which are summarized as:

- general and economic business conditions;
- market prices of oil and gas and expectations about future prices;
- cost of producing and the ability to deliver oil and natural gas;
- the level of drilling and production activity;
- mergers, consolidations and downsizing among our clients;
- coordination by OPEC;
- the impact of commodity prices on the expenditure levels of our clients;
- financial condition of our client base and their ability to fund capital expenditures;
- the physical effects of climatic change, including adverse weather or geologic/geophysical conditions;
- the adoption of legal requirements or taxation relating to climate change that lower the demand for petroleum-based fuels;
- civil unrest or political uncertainty in oil producing or consuming countries;
- level of consumption of oil, gas and petrochemicals by consumers;
- changes in existing laws, regulations, or other governmental actions;
- the business opportunities (or lack thereof) that may be presented to and pursued by us;
- availability of services and materials for our clients to grow their capital expenditures;
- availability of materials and equipment from key suppliers; and
- cyber attacks on our network that disrupt operations or result in lost or compromised critical data.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in the forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed discussion of some of the foregoing risks and uncertainties, see "Item 1A - Risk Factors" in our 2012 Annual Report and in Part II of this document, as well as the other reports filed by us with the Securities and Exchange Commission ("SEC").

## Outlook

We continue our efforts to expand our market presence by opening or expanding facilities in strategic areas and realizing synergies within our business lines. We believe our market presence provides us a unique opportunity to service clients who have global operations in addition to the national oil companies.

We have established internal earnings targets that are based on market conditions existing at the time our targets were established. Based on recent activity levels, we believe that the current level of activities, workflows, and operating margins within North America will remain similar to that experienced in the first half of 2013, but we believe activity outside North America, particularly those relating to oil development projects, will grow moderately throughout 2013.

## **Results of Operations**

Our results of operations as a percentage of applicable revenue were as follows (in thousands):

(Unaudited)		% Change						
	2013				2012	2	2013/2012	
REVENUE:								
Services	\$	187,676	71%	\$	175,749	71%	7 %	
Product sales		75,463	29%		71,257	29%	6 %	
Total revenue		263,139	100%		247,006	100%	7 %	
OPERATING EXPENSES:								
Cost of services, exclusive of depreciation expense shown below*		109,661	58%		103,926	59%	6 %	
Cost of product sales, exclusive of depreciation expense shown below*		53,842	71%		52,454	74%	3 %	
Total cost of services and product sales		163,503	62%		156,380	63%	5 %	
General and administrative expenses		11,173	4%		10,205	4%	9 %	
Depreciation and amortization		5,964	2%		5,077	2%	17 %	
Other (income) expense, net		630	%		3,218	1%	(80)%	
Operating income		81,869	31%		72,126	29%	14 %	
Interest expense		2,263	1%		2,178	1%	4 %	
Income before income tax expense		79,606	30%		69,948	28%	14 %	
Income tax expense		19,664	7%		16,997	7%	16 %	
Net income		59,942	23%		52,951	21%	13 %	
Net income (loss) attributable to non-controlling interests		266	%		35	%	660 %	
Net income attributable to Core Laboratories N.V.	\$	59,676	23%	\$	52,916	21%	13 %	
	. 1			_				

\* Percentage based on applicable revenue rather than total revenue.

(Unaudited)				% Change		
	2013			201	2013/2012	
REVENUE:						
Services	\$	370,157	71%	\$ 338,418	70 %	9 %
Product sales		153,909	29%	142,779	30 %	8 %
Total revenue		524,066	100%	481,197	100 %	9 %
OPERATING EXPENSES:						
Cost of services, exclusive of depreciation expense shown below*		219,814	59%	201,936	60 %	9 %
Cost of product sales, exclusive of depreciation expense shown below*		107,334	70%	103,584	73 %	4 %
Total cost of services and product sales		327,148	62%	305,520	63 %	7 %
General and administrative expenses		23,982	5%	20,379	4 %	18 %
Depreciation and amortization		11,989	2%	10,960	2 %	9 %
Other (income), net		41	%	(1,694)	<u> </u>	(102)%
Operating income		160,906	31%	146,032	30 %	10 %
Interest expense		4,532	1%	4,368	1 %	4 %
Income before income tax expense		156,374	30%	141,664	29 %	10 %
Income tax expense		39,700	8%	34,783	7 %	14 %
Net income		116,674	22%	106,881	22 %	9 %
Net income (loss) attributable to non-controlling interests		482	%	14	%	3,343 %
Net income attributable to Core Laboratories N.V.	\$	116,192	22%	\$ 106,867	22 %	9 %
* Percentage based on applicable revenue rather than to	tal r					

\* Percentage based on applicable revenue rather than total revenue.

# Operating Results for the Three and Six Months Ended June 30, 2013 Compared to the Three and Six Months Ended June 30, 2012 (unaudited)

#### Services Revenue

Services revenue increased to \$187.7 million for the second quarter of 2013, up 7% when compared to \$175.7 million for the second quarter of 2012. For the six months ended June 30, 2013, services revenue increased to \$370.2 million, up 9% when compared to \$338.4 million for the same period of 2012. The increase in services revenue was primarily due to our continued focus on worldwide crude-oil related and large natural gas for liquefaction projects, especially those related to the development of deepwater fields offshore West and East Africa, the eastern Mediterranean, and the Gulf of Mexico.

## **Product Sales Revenue**

Revenue associated with product sales was up almost 6% to \$75.5 million for the second quarter of 2013, compared to \$71.3 million for the second quarter of 2012. For the six months ended June 30, 2013, product sales revenues increased to \$153.9 million, up 8% from the same period in 2012. The increase in revenue was due to projects providing permanent reservoir monitoring systems to the oil sands in Canada and greater market penetration of our patented and proprietary perforating technologies despite the decline in drilling activity in North America. North America rig count was down over 10% this quarter compared to the same quarter of last year.

## **Cost of Services**

Cost of services expressed as a percentage of services revenue was 58% for the quarter ended June 30, 2013, an improvement from 59% in the same period in 2012. For the six months ended June 30, 2013, cost of services expressed as a percentage of services revenue was 59%, an improvement from 60% in the same period in 2012.

## **Cost of Product Sales**

Cost of product sales expressed as a percentage of product sales revenue was 71% for the quarter ended June 30, 2013, an improvement from 74% during the same period in 2012. For the six months ended June 30, 2013, cost of product sales expressed as a percentage of product sales revenue was 70%, an improvement from 73% during the same period in 2012. The decrease in cost of sales as a percentage of product sales revenue was primarily due to the growing demand for our new technologies which led to an overall increase in sales, which improved absorption of our fixed cost structure.

#### **General and Administrative Expenses**

General and administrative ("G&A") expenses include corporate management and centralized administrative services that benefit our operations. G&A expenses for the second quarter of 2013 were 4.2% of revenue, an increase from the second quarter of 2012 when these expenses represented 4.1% of revenue. For the six months ended June 30, 2013, G&A expenses were 4.6% of revenue, an increase from the same period in 2012 when they were 4.2% of revenue. The increase for the six months ended June 30, 2013 was primarily attributable to employee benefit expenses recorded during the first quarter of 2013.

#### **Depreciation and Amortization Expense**

Depreciation and amortization expense was \$6.0 million for the second quarter of 2013 compared to \$5.1 million in the second quarter of 2012. For the six months ended June 30, 2013, depreciation and amortization expense was \$12.0 million compared to \$11.0 million for the same period in 2012.

## Other (Income) Expense, Net

The components of other (income) expense, net, were as follows (in thousands):

	۲	Three Months E June 30,	nded	Six Months Ended June 30,			
	2	2013	2012	2013	2012		
		(Unaudited)	)	(Unaudit	ted)		
(Gain) loss on sale of assets	\$	(323) \$	(227) \$	(532) \$	(313)		
Results of non-consolidated subsidiaries		(89)	(181)	(185)	(247)		
Foreign exchange (gain) loss		1,631	1,355	2,522	330		
Interest income		(219)	(13)	(590)	(15)		
Rents and royalties		(213)	(255)	(443)	(595)		
(Gain) loss on insurance recovery		(7)	(101)	(546)	(3,467)		
Legal entity realignment			1,860	—	1,860		
NYSE Euronext Amsterdam listing			683	—	923		
Other, net		(150)	97	(185)	(170)		
Total other (income) expense, net	\$	630 \$	3,218 \$	41 \$	(1,694)		

We incurred property losses during Hurricane Isaac in 2012. During the first quarter of 2013, the insurer agreed to pay \$0.9 million of the claim which resulted in a net gain of \$0.5 million after related expenses and the disposal of the assets. We received this initial payment during the second quarter of 2013 and the insurer is continuing to review the remainder of the claim.

During the second quarter of 2012, we incurred legal, accounting and other fees in connection with the realignment of certain of our legal entities into a more cost effective structure and the listing of our shares on the NYSE Euronext Amsterdam Stock Exchange.

As a result of a supply disruption in 2011 from a key vendor that provided certain high performance specialty steel tubulars used with our perforating systems, we filed a claim under our business interruption insurance policy. We recorded a gain of \$3.4 million in the first quarter of 2012 when the initial payment was received from the insurance carrier.

Foreign exchange (gain) loss by currency is summarized in the following table (in thousands):

	,	Three Mor June		Six Months Ended June 30,					
		2013		2012		2013		2012	
		(Unau	d)		(Unaudited)				
Australian Dollar	\$	164	\$	(11)	\$	209	\$	(15)	
British Pound		79		48		541		59	
Canadian Dollar		665		519		968		(18)	
Euro		126		238		354		(7)	
Malaysian Ringgit		106		130		188		79	
Mexican Peso		191		191		64		39	
Russian Ruble		(60)		(16)		(54)		(56)	
Other currencies, net		360		256		252		249	
Total (gain) loss	\$	1,631	\$	1,355	\$	2,522	\$	330	

#### **Interest Expense**

Interest expense for the three months ended June 30, 2013 and 2012 was \$2.3 million and \$2.2 million, respectively. Interest expense for the six months ended June 30, 2013 and 2012 was \$4.5 million and \$4.4 million, respectively.

#### **Income Tax Expense**

The effective tax rates for the three months ended June 30, 2013 and 2012 were 24.7% and 24.3%, respectively. The effective tax rates for the year-to-date 2013 and 2012 were 25.4% and 24.6%, respectively. Included in the six months ended June 30, 2012 is the reversal of \$1.1 million in tax valuation allowance related to various jurisdictions.

## **Segment Analysis**

Our operations are managed primarily in three complementary segments - Reservoir Description, Production Enhancement and Reservoir Management. The following tables summarize our results by operating segment for the three and six months ended June 30, 2013 and 2012 (in thousands):

	Three Months Ended June 30,						
	2013			2012	2013/2012		
Revenue:	(Unaudited)						
Reservoir Description	\$	129,222	\$	126,462	2 %		
Production Enhancement		110,199		99,547	11 %		
Reservoir Management		23,718		20,997	13 %		
Consolidated	\$	263,139	\$	247,006	7 %		
Operating income (loss):							
Reservoir Description	\$	36,918	\$	38,076	(3)%		
Production Enhancement		37,239		29,564	26 %		
Reservoir Management		7,475		7,113	5 %		
Corporate and Other <sup>1</sup>		237		(2,627)	NM		
Consolidated	\$	81,869	\$	72,126	14 %		

(1) "Corporate and Other" represents those items that are not directly related to a particular segment

"NM" means not meaningful

	Si	June 30,	% Change				
	2013			2012	2013/2012		
Revenue:	(Unaudited)						
Reservoir Description	\$	254,467	\$	242,568	5%		
Production Enhancement		217,630		196,280	11%		
Reservoir Management		51,969		42,349	23%		
Consolidated	\$	524,066	\$	481,197	9%		
Operating income (loss):							
Reservoir Description	\$	71,769	\$	70,491	2%		
Production Enhancement		71,477		63,095	13%		
Reservoir Management		17,321		15,028	15%		
Corporate and Other <sup>1</sup>		339		(2,582)	NM		
Consolidated	\$	160,906	\$	146,032	10%		

(1) "Corporate and Other" represents those items that are not directly related to a particular segment

"NM" means not meaningful

#### **Reservoir Description**

Revenue from the Reservoir Description segment increased 2%, or \$2.8 million, to \$129.2 million in the second quarter of 2013, compared to \$126.5 million in the second quarter of 2012. For the six months ended June 30, 2013, revenues increased 5%, or \$11.9 million, to \$254.5 million, compared to \$242.6 million for the same period of 2012. This segment's operations, which focus on international crude-oil related products, continued to benefit from increased activity in large-scale core analyses and reservoir fluids characterization studies in the Asia-Pacific areas, offshore West and East Africa, the Eastern Mediterranean region, the Middle East, including Iraq, Kuwait, and the United Arab Emirates, and deepwater Gulf of Mexico.

Operating income in the second quarter of 2013 decreased by 3%, or \$1.2 million, to \$36.9 million compared to \$38.1 million for the second quarter of 2012. Operating income for the six months ended June 30, 2013 increased by 2%, or \$1.3 million, to \$71.8 million compared to \$70.5 million for the same period of 2012. This increase is a result of higher sales, including a better mix of projects aimed at more complex reservoirs. Operating margin for the quarter ended June 30, 2013 was 29%. This segment emphasizes technologically demanding services on internationally-based development and production-related crude oil projects over the more cyclical exploration-related projects.

#### **Production Enhancement**

Revenue from the Production Enhancement segment increased by 11%, or \$10.7 million, to \$110.2 million in the second quarter of 2013 compared to \$99.5 million in the second quarter of 2012. Revenues increased by 11%, or \$21.4 million, to \$217.6 million for the six months ended June 30, 2013, compared to \$196.3 million for the same period in 2012. The revenue increase was primarily due to demand for our diagnostic services, both for fracture diagnostics in North America and flood diagnostics internationally, and our patented perforating system technology.

Operating income in the second quarter of 2013 increased by 26%, or \$7.7 million, to \$37.2 million from \$29.6 million for the second quarter of 2012. For the six months ended June 30, 2013, operating income increased by 13%, to \$71.5 million over the same period of 2012. Operating margins were 34% in the second quarter of 2013. The increase in operating income from 2012 to 2013 was primarily driven by increased demand for the company's proprietary and patented hydraulic fracture and field-flood diagnostic technologies such as SpectraChem<sup>™</sup>, ZeroWash<sup>™</sup>, and SpectraFlood<sup>™</sup> tracers in North America and internationally.

#### **Reservoir Management**

Revenue from the Reservoir Management segment increased by 13% to \$23.7 million in the second quarter of 2013 compared to \$21.0 million for the second quarter of 2012. Revenue for the six months ended June 30, 2013 increased by 23% to \$52.0 million compared to \$42.3 million for the same period in 2012. The increase in revenue was due to the instrumenting of two oil sands projects in Canada for permanent reservoir monitoring and ongoing interest in several of our existing multiclient reservoir studies such as the *Duvernay Shale Project* in Canada and the *Tight Oil Reservoirs of the Midland Basin* study as well as our new industry project to evaluate the potential of the Pearsall shale, which underlies the shallow portions of the Eagle Ford shale in South Texas.

Operating income in the second quarter of 2013 increased 5% to \$7.5 million from \$7.1 million for the second quarter of 2012. For the six months ended June 30, 2013, operating income was \$17.3 million compared to \$15.0 million for the same period in 2012. Operating margins were 32% in the second quarter of 2013. The increase in operating income in the second quarter of 2013 was primarily a result of additional participants in our joint industry projects, including the Utica, Duvernay, and Mississippi Lime studies and the Marcellus, Niobrara, Wolfcamp and Eagle Ford plays, and the installation of permanent reservoir monitoring systems in Canada.

#### Liquidity and Capital Resources

#### General

We have historically financed our activities through cash on hand, cash flows from operations, bank credit facilities, or the issuance of debt and equity financing.

We utilize the non-GAAP financial measure of free cash flow to evaluate our cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures. Management believes that free cash flow provides useful information to investors regarding the cash that was available in the period that was in excess of our needs to fund our capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP, and should not be considered in isolation nor construed as an alternative to operating profit, net income (loss) or cash flows from operating, investing or financing activities, each as determined in accordance with GAAP. Free cash flow does not represent residual cash available for distribution because we may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented, may not be comparable to similarly titled measures presented by other companies. The following table reconciles this non-GAAP financial measure to the most directly comparable measure calculated and presented in accordance with GAAP for the six months ended June 30, 2013 and 2012 (in thousands):

	Six Months Ended June 30,			% Change	
		2013		2012	2013/2012
Free cash flow calculation:		(Unau	dited	)	
Net cash provided by operating activities	\$	136,501	\$	100,894	35%
Less: cash paid for capital expenditures		17,935		14,894	20%
Free cash flow	\$	118,566	\$	86,000	38%

The increase in free cash flow for the first six months of 2013 compared to the same period in 2012 was primarily due to an increase in cash from operations.

## **Cash Flows**

The following table summarizes cash flows for the six months ended June 30, 2013 and 2012 (in thousands):

	Six Months Ended June 30,			% Change	
		2013		2012	2013/2012
Cash provided by/(used in):		(Unau	dited)		
Operating activities	\$	136,501	\$	100,894	35 %
Investing activities		(20,994)		(14,754)	42 %
Financing activities		(111,513)		(92,064)	21 %
Net change in cash and cash equivalents	\$	3,994	\$	(5,924)	(167)%

The increase in cash flows from operating activities for the first six months of 2013 compared to the same period in 2012 was primarily attributable to an increase in net income and changes in current liabilities and prepaid expenses and other current assets.

Cash flows used in investing activities were higher during the first six months of 2013 when compared to the same period in 2012 primarily due to an increase of \$3.0 million in capital expenditures to \$17.9 million up from \$14.9 million for the six month periods ended June 30, 2013 and 2012, respectively.

Cash flows used in financing activities increased for the first six months of 2013 when compared to the same period in 2012. During the first six months of 2013, we repurchased 742,510 shares of our common stock for an aggregate purchase price of \$100.4 million compared to the repurchase of 403,383 shares for an aggregate purchase price of \$50.2 million during the same period in 2012. In the first six months of 2013, we increased the amount outstanding on our Credit Facility by \$16.0 million, as compared to reducing it by \$18.7 million during the first six months of 2012.

## Notes, Credit Facilities and Available Future Liquidity

In 2011, we issued two series of senior notes with an aggregate principal amount of \$150 million ("Senior Notes") in a private placement transaction. Series A consists of \$75 million in aggregate principal amount of notes that bear interest at a fixed rate of 4.01% and are due in full on September 30, 2021. Series B consists of \$75 million in aggregate principal amount of notes that bear interest at a fixed rate of 4.11% and are due in full on September 30, 2023. Interest on each series of the Senior Notes is payable semi-annually on March 30 and September 30.

We maintain a credit facility (the "Credit Facility") with an aggregate borrowing capacity of \$300 million at June 30, 2013. The Credit Facility provides an option to increase the commitment under the Credit Facility to \$350 million if certain conditions are met. The Credit Facility bears interest at variable rates from LIBOR plus 1.50% to a maximum of LIBOR plus 2.25%. Any outstanding balance under the Credit Facility is due September 28, 2016 when the Credit Facility matures. Interest payment terms are variable depending upon the specific type of borrowing under the Credit Facility. Our available capacity at any point in time is reduced by borrowings outstanding at the time and outstanding letters of credit which totaled \$18.7 million at June 30, 2013, resulting in an available borrowing capacity under the Credit Facility of \$181.3 million. In addition to those items under the Credit Facility, we had \$21.9 million of outstanding letters of credit and performance guarantees and bonds from other sources as of June 30, 2013.

The terms of the Credit Facility and the Senior Notes require us to meet certain financial and operational covenants, including, but not limited to, certain operational and minimum equity and cash flow ratios. We believe that we are in compliance with all such covenants contained in our credit agreements. Certain of our material, wholly-owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes.

Our ability to maintain and grow our operating income and cash flow depends, to a large extent, on continued investing activities. We are a Netherlands holding company and substantially all of our operations are conducted through subsidiaries. Consequently, our cash flow depends upon the ability of our subsidiaries to pay cash dividends or otherwise distribute or advance funds to us. We believe our future cash flows from operations, supplemented by our borrowing capacity and issuances of additional equity, should be sufficient to fund our debt requirements, capital expenditures, working capital, dividend payments and future acquisitions.

#### **Recent Accounting Pronouncements**

In February 2013, the FASB issued ASU 2013-02 relating to comprehensive income (FASB ASC Topic 220), which requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component (the respective line items of net income). This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. We adopted this pronouncement for our fiscal year beginning January 1, 2013. The adoption of this pronouncement did not have a material effect on our consolidated financial statements.

#### Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in market risk from the information provided in Item 7A. "Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.

#### **Item 4. Controls and Procedures**

A complete discussion of our controls and procedures is included in our Annual Report on Form 10-K for the year ended December 31, 2012.

#### **Disclosure Controls and Procedures**

Our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of the end of the period covered by this report. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2013 at the reasonable assurance level.

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. Further, the design of disclosure controls and internal control over financial reporting must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

#### **Changes in Internal Control Over Financial Reporting**

There have been no changes in our system of internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the fiscal quarter ended June 30, 2013, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

#### CORE LABORATORIES N.V.

## **PART II - OTHER INFORMATION**

#### **Item 1. Legal Proceedings**

See Note 6 to our Consolidated Interim Financial Statements in Part I, Item 1 of this Quarterly Report on Form 10-Q.

#### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information about purchases of equity securities that are registered by us pursuant to Section 12 of the Exchange Act during the quarter ended June 30, 2013:

Period	Total Number of Shares Purchased	verage Price Paid Per Share	Total Number of Shares Purchased as Part of a Publicly Announced Program	Maximum Number of Shares That May Yet be Purchased Under the Program (4)
April 30, 2013 (1)	167,600	\$ 133.66	167,600	2,771,144
May 31, 2013 (2)	90,260	143.46	90,260	2,685,234
June 30, 2013 (3)	120,109	 144.21	120,109	2,599,625
Total	377,969	\$ 139.35	377,969	

(1) Contains 10,100 shares valued at approximately \$1.4 million, or \$134.12 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in April 2013.
(2) Contains 260 shares valued at approximately \$36.9 thousand, or \$141.90 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in May 2013.
(3) Contains 10,109 shares valued at approximately \$1.5 million, or \$151.66 per share, surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award in June 2013.
(4) In connection with our initial public offering in September 1995, our shareholders authorized our Management Board to repurchase up to 10% of our issued share capital for a period of 18 months. This authorization was renewed at subsequent annual or special shareholder meetings. At our annual shareholders' meeting on May 16, 2013, our shareholders authorized an extension to repurchase 10% of our issued share capital through November 16, 2014. The repurchase of shares in the open market is at the discretion of management pursuant to this shareholder authorization.

Exhibit No.		Exhibit Title	Incorporated by reference from the following documents
3.1	-	Articles of Association of Core Laboratories N.V., as amended (including English translation)	Exhibit 3.1 filed on February 19, 2013 with 2012 10-K (File No. 001-14273)
31.1	-	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
31.2	-	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
32.1	-	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith
32.2	-	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith
101.INS	-	XBRL Instance Document	Filed herewith
101.SCH	-	XBRL Schema Document	Filed herewith
101.CAL	-	XBRL Calculation Linkbase Document	Filed herewith
101.LAB	-	XBRL Label Linkbase Document	Filed herewith
101.PRE	-	XBRL Presentation Linkbase Document	Filed herewith
101.DEF	-	XBRL Definition Linkbase Document	Filed herewith

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, Core Laboratories N.V., has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

## **CORE LABORATORIES N.V.**

Date: July 19, 2013

By: /s/ Richard L. Bergmark

Richard L. Bergmark Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer)